ALFA Finder| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | 36% YoY growth driven by acquisitions and new product launches. |
|---|---|
| Margins | EBITDA margins stable at 26%; expected range 22-26% consolidated. |
| Order book | ₹18,000 Cr potential business over respective tenures via LOIs. |
| Demand visibility | Strong demand in Pharma and Performance Materials; Agro recovery underway. |
| Management confidence | Balanced; focused on integration and commercializing the existing pipeline. |
Growth
Total income grew 36% YoY to ₹668 Cr; EBITDA margins remained stable at 26%.
Outlook
Management guides 20-25% organic revenue growth plus J-Hock contributions for FY27.
Risks
Higher depreciation and interest costs from acquisitions are suppressing net profit growth (only 6% YoY).
Last quarter's promises, checked
Delivered
- Guided 20-25% CAGR → delivered 65% YoY revenue growth (= BEAT)
- Guided improved working capital → delivered ₹334 Cr operating cash flow (= BEAT)
- Guided no major capex → delivered ₹315 Cr final leg completion (= BEAT)
Partly delivered
- Guided 25% tax rate → delivered sharp reduction but specific rate varies by entity (= PARTIAL)
Missed
- Guided 24-25% EBITDA margin → delivered 23% for FY26 (= MISS)
Earnings Call Transcript filed with BSE, NSE: ANURAS. Summary written with AI assistance from the document.
Anupam Rasayan India Ltd: key numbers
- Share price
- ₹1,196.20
- Market cap
- ₹13,619 Cr
- Revenue (annual)
- ₹2,365 Cr
- Net profit (annual)
- ₹170.1 Cr
- P/E (TTM)
- 75.5×Sector 35.5×
- Promoter holding
- 59.07%+0.00% QoQ
- FII holding
- 8.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anupam Rasayan India Ltd
All →Anupam Rasayan India Earnings Call Transcript: Key Takeaways
Q2 income up 11% to ₹821 Cr; EBITDA up 41% to ₹202 Cr at 25% margin. Bliss GVS closed 28 Sep, so only three days are consolidated. Management avoided quantifying Bliss and M&A.
Anupam Rasayan India Investor Presentation: Key Takeaways
Q2FY27 consolidated total income ₹821 Cr (+11% YoY), EBITDA ₹202 Cr (+41%, 25% margin), PAT ₹65 Cr (+14%). Controlling stake in Bliss GVS Pharma acquired 28 Sep 2026.
Anupam Rasayan India Q2 FY27 Results: Net Profit ₹65 Cr, Up 13.6% YoY
Anupam Rasayan India Ltd reported revenue from operations of ₹805.9 Cr (+10.2% YoY) and net profit of ₹65 Cr (+13.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65 Cr · +13.6% YoY
Anupam Rasayan India Board Meeting Date
Anupam Rasayan India scheduled a November 6, 2026 board meeting to approve unaudited standalone and consolidated results. The trading window stays closed until November 8.
Anupam Rasayan India Annual General Meeting
Anupam Rasayan India Limited filed copy of minutes of its Annual General Meeting held on September 30, 2026. The filing is procedural and carries no financial or business event.
Anupam Rasayan India Other Announcement
Anupam Rasayan India disclosed a Crisil ESG rating of 62 and Core ESG rating of 63 (Strong). No transaction or business decision is involved.